-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, MIYBzB7ARpZsCJN3CTivxBYdj2IEBAI3o6qfdpX1HhVjl/wnlV8EY9Q6nwDE0EOs XKimM+eDcYBUdXvZFKnu8w== 0000950123-05-010360.txt : 20050825 0000950123-05-010360.hdr.sgml : 20050825 20050825165536 ACCESSION NUMBER: 0000950123-05-010360 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20050825 DATE AS OF CHANGE: 20050825 GROUP MEMBERS: BIOMEDICAL OFFSHORE VALUE FUND LTD. GROUP MEMBERS: BIOMEDICAL VALUE FUND LP GROUP MEMBERS: DR. JEFFREY R. JAY MD FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: GREAT POINT PARTNERS LLC CENTRAL INDEX KEY: 0001281446 IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A MAIL ADDRESS: STREET 1: 2 PICKWICK PLAZA STREET 2: STE 450 CITY: GREENWICH STATE: CT ZIP: 06830 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: PANACOS PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001040017 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 113238476 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-55237 FILM NUMBER: 051049427 BUSINESS ADDRESS: STREET 1: 134 COOLIDGE AVE CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617-926-1551 MAIL ADDRESS: STREET 1: 134 COOLIDGE AVE CITY: WATERTOWN STATE: MA ZIP: 02472 FORMER COMPANY: FORMER CONFORMED NAME: V I TECHNOLOGIES INC DATE OF NAME CHANGE: 19980209 SC 13D/A 1 y12294sc13dza.txt AMENDMENT NO. 3 TO SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Panacos Pharmaceuticals, Inc. --------------------------------------- (Name of Issuer) Common Stock --------------------------------------- (Title of Class of Securities) 917920 10 0 --------------------------------------- (CUSIP Number) Dr. Jeffrey R. Jay, MD Great Point Partners, LLC 2 Pickwick Plaza, Suite 450 Greenwich, CT 06830 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) August 22, 2005 --------------------------------------- (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Sections 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box [ ]. NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Section 240.13d-7 for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 917920 10 0 Page 2 of 8 - -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON Great Point Partners, LLC S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A (a) [ ] MEMBER OF A GROUP (b) [ ] - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS Not applicable - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL [ ] PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware, USA - -------------------------------------------------------------------------------- NUMBER OF 7 SOLE VOTING POWER 0 SHARES ------------------------------------------------------------- BENEFICIALLY 8 SHARED VOTING POWER 4,240,932 OWNED BY ------------------------------------------------------------- EACH 9 SOLE DISPOSITIVE POWER 0 REPORTING ------------------------------------------------------------- PERSON 10 SHARED DISPOSITIVE POWER 4,240,932 WITH - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY 4,240,932 OWNED BY EACH REPORTING PERSON - -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN [ ] ROW (11) EXCLUDES CERTAIN SHARES - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY 10.06%* AMOUNT IN ROW (11) - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON OO CUSIP No. 917920 10 0 Page 3 of 8 - -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON Biomedical Value Fund, S.S. OR I.R.S. IDENTIFICATION NO. L.P. OF ABOVE PERSON - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A (a) [ ] MEMBER OF A GROUP (b) [ ] - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS Not applicable - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL [ ] PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware, U.S.A - -------------------------------------------------------------------------------- NUMBER OF 7 SOLE VOTING POWER 1,904,182 SHARES ----------------------------------------------------------------- BENEFICIALLY 8 SHARED VOTING POWER 0 OWNED BY ----------------------------------------------------------------- EACH 9 SOLE DISPOSITIVE POWER 1,904,182 REPORTING ----------------------------------------------------------------- PERSON 10 SHARED DISPOSITIVE POWER 0 WITH - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY 1,904,182 OWNED BY EACH REPORTING PERSON - -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN [ ] ROW (11) EXCLUDES CERTAIN SHARES - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY 4.66%* AMOUNT IN ROW (11) - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON PN CUSIP No. 917920 10 0 Page 4 of 8 - -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON Biomedical Offshore S.S. OR I.R.S. IDENTIFICATION NO. Value Fund, Ltd. OF ABOVE PERSON - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A (a) [ ] MEMBER OF A GROUP (b) [ ] - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS Not applicable - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL [ ] PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION Cayman Islands - -------------------------------------------------------------------------------- NUMBER OF 7 SOLE VOTING POWER 2,336,750 SHARES ----------------------------------------------------------------- BENEFICIALLY 8 SHARED VOTING POWER 0 OWNED BY ----------------------------------------------------------------- EACH 9 SOLE DISPOSITIVE POWER 2,336,750 REPORTING ----------------------------------------------------------------- PERSON 10 SHARED DISPOSITIVE POWER 0 WITH - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY 2,336,750 OWNED BY EACH REPORTING PERSON - -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN [ ] ROW (11) EXCLUDES CERTAIN SHARES - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY 5.73%* AMOUNT IN ROW (11) - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON CO CUSIP No. 917920 10 0 Page 5 of 8 - -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON Dr. Jeffrey R. Jay, M.D. S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A (a) [ ] MEMBER OF A GROUP (b) [ ] - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS Not applicable - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL [ ] PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION United States - -------------------------------------------------------------------------------- NUMBER OF 7 SOLE VOTING POWER 90,625 SHARES ----------------------------------------------------------------- BENEFICIALLY 8 SHARED VOTING POWER 4,240,932 OWNED BY ----------------------------------------------------------------- EACH 9 SOLE DISPOSITIVE POWER 90,625 REPORTING ----------------------------------------------------------------- PERSON 10 SHARED DISPOSITIVE POWER 4,240,932 WITH - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY 4,331,557 OWNED BY EACH REPORTING PERSON - -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN [ ] ROW (11) EXCLUDES CERTAIN SHARES - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY 10.27%* AMOUNT IN ROW (11) - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON IN * The calculation of the foregoing percentages is based on 39,509,667 shares of Common Stock outstanding as of July 15, 2005, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 15, 2005. CUSIP No. 917920 10 0 Page 6 of 8 AMENDMENT NO. 2 TO STATEMENT ON SCHEDULE 13D FILED BY GREAT POINT PARTNERS, LLC. This Amendment No. 3 amends and supplements Item 5 of the Schedule 13D, dated March 11, 2005 (the "Schedule 13D") filed by Great Point Partners, LLC ("Great Point"), Biomedical Value Fund, L.P. ("BMVF"), Biomedical Offshore Value Fund, Ltd. ("BOVF") and Dr. Jeffrey R. Jay, M.D. ("Dr. Jay"), as amended by Amendment No. 1 thereto filed on July 13, 2005 and Amendment No. 2 thereto filed on July 22, 2005, with respect to the shares of common stock, par value $0.01 per share (the "Common Stock") of Panacos Pharmaceuticals, Inc. (formerly V.I. Technologies, Inc.) (the "Issuer"). Item 5 "Interest in Securities of the Issuer" of the Schedule 13D is hereby amended to add the following information: Item 5. Interest in Securities of the Issuer. (a) and (b) As a result of sales conducted on August 22, 2005, August 23, 2005 and August 24, 2005, BMVF is now the beneficial owner of 1,904,182 shares of Common Stock, consisting of 516,884 shares of Common Stock and warrants to purchase 1,387,298 shares of Common Stock. Such shares, in the aggregate, represent 4.66% of the shares of Common Stock outstanding, computed in accordance with Rule 13d-3. BMVF disclaims beneficial ownership of any securities owned by BOVF or Dr. Jay. As a result of sales conducted on August 22, 2005, August 23, 2005 and August 24, 2005, BOVF is now the beneficial owner of 2,336,750 shares of Common Stock, consisting of 1,079,000 shares of Common Stock and warrants to purchase 1,257,750 shares of Common Stock. Such shares, in the aggregate, represent 5.73% of Common Stock outstanding, computed in accordance with Rule 13d-3. BOVF disclaims beneficial ownership of any securities owned by BMVF or Dr. Jay. Great Point is the investment manager of each of BMVF and BOVF, and by virtue of such status has shared voting and investment power with respect to securities owned and held by BMVF and BOVF and may be deemed to be the beneficial owner of such securities. Thus, as a result of the August 22, 2005, August 23, 2005 and August 24, 2005 sales described above, Great Point may now be deemed to be the beneficial owner of 4,240,932 shares of Common Stock, consisting of 1,595,884 shares of Common Stock and warrants to purchase 2,645,048 shares of Common Stock. Such shares, in the aggregate, represent 10.06% of Common Stock outstanding, computed in accordance with Rule 13d-3. Great Point disclaims beneficial ownership of any securities owned by Dr. Jay. Dr. Jay beneficially owns 90,625 shares of Common Stock, consisting of 62,500 shares of Common Stock and warrants to purchase 28,125 shares of Common Stock. In addition, Dr. Jay, as senior managing member of Great Point, has shared voting and investment power with respect to securities owned and held by BMVF and BOVF and may be deemed to be the beneficial owner of such securities. Therefore, as a result of the August 22, 2005, August 23, 2005 and August 24, 2005 sales described above, Dr. Jay may now be deemed to be the beneficial owner of 4,331,557 shares of Common CUSIP No. 917920 10 0 Page 7 of 8 Stock, consisting of an aggregate amount of 1,658,384 shares of Common Stock and warrants to purchase 2,673,173 shares of Common Stock. Such shares, in the aggregate, represent 10.27% of Common Stock outstanding, computed in accordance with Rule 13d-3. Notwithstanding the above, Great Point and Dr. Jay disclaim beneficial ownership of the shares of Common Stock held by BMVF and BOVF, except to the extent of any pecuniary interest, and this Amendment No. 3 to the Schedule 13D shall not be deemed to be an admission that they are the beneficial owners of such securities. (c) The tables set forth information with respect to all sales of Common Stock by each of BMVF and BOVF since the filing of Amendment No. 2 thereto on July 22, 2005. Additional detail regarding such sales is included in Annex A, Annex B and Annex C hereto, and incorporated by reference herein. All of such sales were executed through broker's transactions on NASDAQ. BMVF:
TRANSACTION DATE NUMBER OF SHARES AVERAGE PRICE PER SHARE - ---------------- ---------------- ----------------------- August 22, 2005 1,325,000 $ 10.8615 August 22, 2005 100,000 $ 11.1757 August 23, 2005 35,500 $ 9.5625 August 24, 2005 105,500 $ 9.597
BOVF:
TRANSACTION DATE NUMBER OF SHARES AVERAGE PRICE PER SHARE - ---------------- ---------------- ----------------------- August 22, 2005 475,000 $ 10.8615 August 22, 2005 100,000 $ 11.1757 August 23, 2005 35,500 $ 9.5625 August 24, 2005 105,500 $ 9.597
Item 7. Materials to be Filed as Exhibits Annex A: Details of sales of shares by BMVF and BOVF on August 22, 2005. Annex B: Details of sales of shares by BMVF and BOVF on August 23, 2005. Annex C: Details of sales of shares by BMVF and BOVF on August 24, 2005. Exhibit G: Joint Filing Agreement among Great Point, BMVF, BOVF and Dr. Jay, dated August 25, 2005. Except as expressly amended and supplemented hereby, the text of the Schedule 13D remains in effect without any further modification. CUSIP No. 917920 10 0 Page 8 of 8 SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement with respect to the undersigned is true, complete and correct. Dated: August 25, 2005 GREAT POINT PARTNERS, LLC /s/ Dr. Jeffrey R. Jay, M.D. ---------------------------------- By Dr. Jeffrey R. Jay, M.D., as senior managing member BIOMEDICAL VALUE FUND, L.P. /s/ Dr. Jeffrey R. Jay, M.D. --------------------------------- By Great Point Partners, LLC, as investment manager, By Dr. Jeffrey R. Jay as senior managing member BIOMEDICAL OFFSHORE VALUE FUND, Ltd. /s/ Dr. Jeffrey R. Jay, M.D. --------------------------------- By Great Point Partners, LLC, as investment manager, By Dr. Jeffrey R. Jay, M.D., as senior managing member DR. JEFFREY R. JAY, M.D. /s/ Dr. Jeffrey R. Jay, M.D. --------------------------------- ANNEX A DETAILS OF SALES OF 1,325,000 SHARES BY BMVF ON AUGUST 22, 2005
SHARES PRICE PER SHARE - ------ --------------- 2,946 $ 10.080 920 $ 10.100 368 $ 10.109 5,033 $ 10.110 5,985 $ 10.120 442 $ 10.130 1,030 $ 10.150 662 $ 10.160 291 $ 10.169 883 $ 10.180 367 $ 10.190 607 $ 10.200 158 $ 10.210 1,546 $ 10.219 1,803 $ 10.220 4,858 $ 10.229 1,472 $ 10.230 1,177 $ 10.239 736 $ 10.240 3,294 $ 10.249 5,115 $ 10.250 442 $ 10.259 3,387 $ 10.260 2,871 $ 10.269 4,564 $ 10.270 4,782 $ 10.279 6,294 $ 10.280 3,460 $ 10.289 5,421 $ 10.290 15,972 $ 10.299 10,384 $ 10.300 1,620 $ 10.309 9,457 $ 10.310 737 $ 10.319 4,747 $ 10.320 1,532 $ 10.329 4,818 $ 10.330 9,348 $ 10.339 2,517 $ 10.340 6,091 $ 10.349 18,988 $ 10.350 5,668 $ 10.359 18,497 $ 10.360 5,447 $ 10.369 8,201 $ 10.370 12,736 $ 10.379 12,145 $ 10.380
3,223 $ 10.389 3,902 $ 10.390 4,476 $ 10.399 19,352 $ 10.400 6,331 $ 10.409 4,096 $ 10.410 811 $ 10.419 1,614 $ 10.420 2,356 $ 10.429 8,907 $ 10.430 4,579 $ 10.439 4,369 $ 10.440 2,577 $ 10.449 14,789 $ 10.450 111 $ 10.459 4,785 $ 10.460 8,023 $ 10.466 6,110 $ 10.469 2,864 $ 10.470 1,225 $ 10.479 1,915 $ 10.480 4,785 $ 10.489 7,508 $ 10.490 8,097 $ 10.499 7,803 $ 10.500 5,006 $ 10.509 7,921 $ 10.510 2,138 $ 10.519 7,483 $ 10.520 9,900 $ 10.529 6,148 $ 10.530 5,742 $ 10.539 14,359 $ 10.540 4,458 $ 10.549 11,064 $ 10.550 5,595 $ 10.559 9,938 $ 10.560 1,289 $ 10.569 8,958 $ 10.570 1,399 $ 10.579 5,155 $ 10.580 1,473 $ 10.589 3,063 $ 10.590 995 $ 10.599 10,202 $ 10.600 2,209 $ 10.609 3,254 $ 10.610 1,179 $ 10.619 2,540 $ 10.620 737 $ 10.629 1,106 $ 10.630 5,589 $ 10.639
3,417 $ 10.640 5,779 $ 10.649 27,152 $ 10.650 2,430 $ 10.659 5,484 $ 10.660 479 $ 10.669 1,050 $ 10.670 7,490 $ 10.679 148 $ 10.680 2,577 $ 10.689 663 $ 10.699 47,251 $ 10.700 1,363 $ 10.709 9,056 $ 10.710 2,430 $ 10.719 19,181 $ 10.720 3,460 $ 10.729 443 $ 10.730 1,841 $ 10.739 3,313 $ 10.740 369 $ 10.749 229 $ 10.749 17,588 $ 10.750 1,105 $ 10.760 1,859 $ 10.770 148 $ 10.779 6,105 $ 10.780 8,171 $ 10.789 7,006 $ 10.790 1,841 $ 10.799 14,554 $ 10.800 2,062 $ 10.809 2,132 $ 10.810 185 $ 10.819 2,430 $ 10.820 4,417 $ 10.829 4,417 $ 10.830 75 $ 10.839 3,902 $ 10.840 19,592 $ 10.850 4,417 $ 10.859 4,417 $ 10.860 1,258 $ 10.869 4,976 $ 10.870 1,915 $ 10.879 789 $ 10.880 332 $ 10.889 1,521 $ 10.890 1,620 $ 10.899 295 $ 10.900 3,681 $ 10.910 2,209 $ 10.919
663 $ 10.920 737 $ 10.929 4,564 $ 10.939 1,620 $ 10.940 3,699 $ 10.949 847 $ 10.950 811 $ 10.959 1,605 $ 10.960 3,019 $ 10.969 1,252 $ 10.980 950 $ 10.989 12,803 $ 10.990 11,413 $ 10.999 16,437 $ 11.000 553 $ 11.009 737 $ 11.009 737 $ 11.009 369 $ 11.009 18,960 $ 11.010 3,239 $ 11.019 1,310 $ 11.020 5,061 $ 11.030 1,620 $ 11.039 515 $ 11.040 2,018 $ 11.049 11,004 $ 11.050 295 $ 11.059 7,486 $ 11.060 3,515 $ 11.069 1,031 $ 11.070 2,798 $ 11.079 3,828 $ 11.080 409 $ 11.089 4,417 $ 11.090 1,252 $ 11.099 16,019 $ 11.100 1,727 $ 11.109 1,151 $ 11.110 2,062 $ 11.119 737 $ 11.129 1,619 $ 11.130 6,094 $ 11.139 5,287 $ 11.140 147 $ 11.149 16,104 $ 11.150 736 $ 11.160 883 $ 11.169 1,325 $ 11.170 1,546 $ 11.179 4,114 $ 11.180 368 $ 11.189 37 $ 11.190
5,128 $ 11.199 18,288 $ 11.200 3,386 $ 11.209 3,378 $ 11.210 14,749 $ 11.219 6,525 $ 11.220 2,197 $ 11.229 810 $ 11.230 2,429 $ 11.239 3,827 $ 11.240 13,064 $ 11.249 39,824 $ 11.250 147 $ 11.259 6,102 $ 11.260 2,539 $ 11.269 6,392 $ 11.270 1,472 $ 11.279 442 $ 11.280 110 $ 11.289 1,156 $ 11.290 1,104 $ 11.299 3,901 $ 11.300 1,558 $ 11.320 7,875 $ 11.329 3,827 $ 11.330 6,841 $ 11.339 810 $ 11.340 6,352 $ 11.349 4,387 $ 11.350 1,030 $ 11.359 5,667 $ 11.360 4,449 $ 11.369 3,862 $ 11.370 4,004 $ 11.379 966 $ 11.380 2,208 $ 11.389 405 $ 11.390 36,012 $ 11.400 52 $ 11.410 662 $ 11.420 9,919 $ 11.430 368 $ 11.439 2,117 $ 11.440 6,698 $ 11.449 4,468 $ 11.450 3,018 $ 11.459 76 $ 11.460 4,334 $ 11.469 74 $ 11.479 4,122 $ 11.480 221 $ 11.489 2,716 $ 11.490
3,766 $ 11.500 2,208 $ 11.509 810 $ 11.510 736 $ 11.519 2,944 $ 11.520 5,226 $ 11.529 7,610 $ 11.530 2,282 $ 11.539 2,034 $ 11.540 3,963 $ 11.549 5,167 $ 11.550 1,619 $ 11.559 1,862 $ 11.560 37 $ 11.600 736 $ 11.619 1,914 $ 11.629 3,340 $ 11.700 443 $ 11.710 4,417 $ 11.719 148 $ 11.720 369 $ 11.729 737 $ 11.750 1,547 $ 11.790 737 $ 11.809 104 $ 11.820 958 $ 11.839 3,085 $ 11.900 737 $ 11.909 517 $ 11.919 76 $ 11.920 76 $ 11.929 1,839 $ 11.950 789 $ 11.960 1,250 $ 11.970 1,841 $ 11.979 2,135 $ 11.980 3,232 $ 11.990 2,798 $ 11.999 29,362 $ 12.000
DETAILS OF SALES OF 100,000 SHARES BY BMVF ON AUGUST 22, 2005
SHARES PRICE PER SHARE - ------ --------------- 32,645 $ 11.00 250 $ 11.01 7,500 $ 11.05 5,307 $ 11.08 1,083 $ 11.09 1,500 $ 11.10 8,215 $ 11.12 200 $ 11.13 2,750 $ 11.14 550 $ 11.15 1,150 $ 11.20 3,500 $ 11.21 1,870 $ 11.35 4,016 $ 11.38 175 $ 11.39 1,230 $ 11.40 976 $ 11.41 1,394 $ 11.42 950 $ 11.43 600 $ 11.44 1,349 $ 11.45 50 $ 11.46 275 $ 11.47 25 $ 11.50
DETAILS OF SALES OF 475,000 SHARES BY BOVF ON AUGUST 22, 2005
SHARES PRICE PER SHARE - ------ --------------- 1,054 $ 10.080 330 $ 10.100 132 $ 10.109 1,805 $ 10.110 2,145 $ 10.120 158 $ 10.130 370 $ 10.150 238 $ 10.160 105 $ 10.169 317 $ 10.180 133 $ 10.190 218 $ 10.200 56 $ 10.210 554 $ 10.219 647 $ 10.220 1,742 $ 10.229 528 $ 10.230 423 $ 10.239 264 $ 10.240 1,181 $ 10.249 1,835 $ 10.250 158 $ 10.259 1,213 $ 10.260 1,029 $ 10.269 1,636 $ 10.270 1,712 $ 10.279 2,256 $ 10.280 1,240 $ 10.289 1,943 $ 10.290 5,728 $ 10.299 3,723 $ 10.300 580 $ 10.309 3,391 $ 10.310 263 $ 10.319 1,702 $ 10.320 548 $ 10.329 1,727 $ 10.330 3,352 $ 10.339 902 $ 10.340 2,183 $ 10.349 6,810 $ 10.350 2,032 $ 10.359 6,633 $ 10.360 1,953 $ 10.369 2,940 $ 10.370 4,567 $ 10.379 4,355 $ 10.380 1,155 $ 10.389 1,398 $ 10.390
1,604 $ 10.399 6,940 $ 10.400 2,269 $ 10.409 1,468 $ 10.410 289 $ 10.419 578 $ 10.420 844 $ 10.429 3,193 $ 10.430 1,641 $ 10.439 1,566 $ 10.440 923 $ 10.449 5,303 $ 10.450 39 $ 10.459 1,715 $ 10.460 2,877 $ 10.466 2,190 $ 10.469 1,026 $ 10.470 438 $ 10.479 685 $ 10.480 1,715 $ 10.489 2,692 $ 10.490 2,903 $ 10.499 2,797 $ 10.500 1,794 $ 10.509 2,840 $ 10.510 765 $ 10.519 2,683 $ 10.520 3,550 $ 10.529 2,204 $ 10.530 2,058 $ 10.539 5,149 $ 10.540 1,598 $ 10.549 3,967 $ 10.550 2,005 $ 10.559 3,564 $ 10.560 461 $ 10.569 3,212 $ 10.570 501 $ 10.579 1,848 $ 10.580 527 $ 10.589 1,097 $ 10.590 355 $ 10.599 3,658 $ 10.600 791 $ 10.609 1,166 $ 10.610 421 $ 10.619 910 $ 10.620 263 $ 10.629 395 $ 10.630 2,004 $ 10.639 1,224 $ 10.640 2,071 $ 10.649
9,738 $ 10.650 870 $ 10.659 1,966 $ 10.660 171 $ 10.669 375 $ 10.670 2,685 $ 10.679 52 $ 10.680 923 $ 10.689 237 $ 10.699 16,948 $ 10.700 487 $ 10.709 3,247 $ 10.710 870 $ 10.719 6,879 $ 10.720 1,240 $ 10.729 157 $ 10.730 659 $ 10.739 1,187 $ 10.740 131 $ 10.749 81 $ 10.749 6,307 $ 10.750 395 $ 10.760 665 $ 10.770 52 $ 10.779 2,189 $ 10.780 2,929 $ 10.789 2,512 $ 10.790 659 $ 10.799 5,219 $ 10.800 738 $ 10.809 763 $ 10.810 65 $ 10.819 870 $ 10.820 1,583 $ 10.829 1,583 $ 10.830 25 $ 10.839 1,398 $ 10.840 7,026 $ 10.850 1,583 $ 10.859 1,583 $ 10.860 450 $ 10.869 1,783 $ 10.870 685 $ 10.879 281 $ 10.880 118 $ 10.889 544 $ 10.890 580 $ 10.899 105 $ 10.900 1,319 $ 10.910 791 $ 10.919 237 $ 10.920 263 $ 10.929
1,636 $ 10.939 580 $ 10.940 1,325 $ 10.949 302 $ 10.950 289 $ 10.959 575 $ 10.960 1,081 $ 10.969 448 $ 10.980 340 $ 10.989 4,591 $ 10.990 4,092 $ 10.999 5,895 $ 11.000 197 $ 11.009 263 $ 11.009 263 $ 11.009 131 $ 11.009 6,800 $ 11.010 1,161 $ 11.019 468 $ 11.020 1,814 $ 11.030 580 $ 11.039 185 $ 11.040 722 $ 11.049 3,946 $ 11.050 105 $ 11.059 2,684 $ 11.060 1,260 $ 11.069 369 $ 11.070 1,002 $ 11.079 1,372 $ 11.080 145 $ 11.089 1,583 $ 11.090 448 $ 11.099 5,744 $ 11.100 618 $ 11.109 411 $ 11.110 738 $ 11.119 263 $ 11.129 581 $ 11.130 2,186 $ 11.139 1,897 $ 11.140 53 $ 11.149 5,776 $ 11.150 264 $ 11.160 317 $ 11.169 475 $ 11.170 554 $ 11.179 1,476 $ 11.180 132 $ 11.189 13 $ 11.190 1,839 $ 11.199 6,560 $ 11.200
1,214 $ 11.209 1,211 $ 11.210 5,291 $ 11.219 2,340 $ 11.220 788 $ 11.229 290 $ 11.230 871 $ 11.239 1,373 $ 11.240 4,686 $ 11.249 14,285 $ 11.250 53 $ 11.259 2,189 $ 11.260 911 $ 11.269 2,293 $ 11.270 528 $ 11.279 158 $ 11.280 40 $ 11.289 414 $ 11.290 396 $ 11.299 1,399 $ 11.300 559 $ 11.320 2,825 $ 11.329 1,373 $ 11.330 2,454 $ 11.339 290 $ 11.340 2,278 $ 11.349 1,573 $ 11.350 370 $ 11.359 2,033 $ 11.360 1,596 $ 11.369 1,385 $ 11.370 1,436 $ 11.379 346 $ 11.380 792 $ 11.389 145 $ 11.390 12,918 $ 11.400 18 $ 11.410 238 $ 11.420 3,558 $ 11.430 132 $ 11.439 760 $ 11.440 2,402 $ 11.449 1,602 $ 11.450 1,082 $ 11.459 28 $ 11.460 1,554 $ 11.469 26 $ 11.479 1,478 $ 11.480 79 $ 11.489 974 $ 11.490 1,351 $ 11.500 792 $ 11.509
290 $ 11.510 264 $ 11.519 1,056 $ 11.520 1,874 $ 11.529 2,730 $ 11.530 818 $ 11.539 729 $ 11.540 1,421 $ 11.549 1,853 $ 11.550 581 $ 11.559 668 $ 11.560 13 $ 11.600 264 $ 11.619 686 $ 11.629 1,198 $ 11.700 157 $ 11.710 1,583 $ 11.719 52 $ 11.720 131 $ 11.729 263 $ 11.750 553 $ 11.790 263 $ 11.809 36 $ 11.820 342 $ 11.839 1,105 $ 11.900 263 $ 11.909 184 $ 11.919 24 $ 11.920 24 $ 11.929 661 $ 11.950 281 $ 11.960 450 $ 11.970 659 $ 11.979 765 $ 11.980 1,158 $ 11.990 1,002 $ 11.999 10,530 $ 12.000
DETAILS OF SALES OF 100,000 SHARES BY BOVF ON AUGUST 22, 2005
SHARES PRICE PER SHARE - ------ --------------- 32,645 $ 11.00 250 $ 11.01 7,500 $ 11.05 5,307 $ 11.08 1,083 $ 11.09 1,500 $ 11.10 8,215 $ 11.12 200 $ 11.13 2,750 $ 11.14 550 $ 11.15 1,150 $ 11.20 3,500 $ 11.21 1,870 $ 11.35 4,016 $ 11.38 175 $ 11.39 1,230 $ 11.40 976 $ 11.41 1,394 $ 11.42 950 $ 11.43 600 $ 11.44 1,349 $ 11.45 50 $ 11.46 275 $ 11.47 25 $ 11.50
ANNEX B DETAILS OF SALE OF 35,500 SHARES BY BMVF ON AUGUST 23, 2005
SHARES PRICE PER SHARE - ------ --------------- 268 $ 9.150 10,057 $ 9.500 350 $ 9.509 1,155 $ 9.510 1,100 $ 9.529 695 $ 9.530 3,050 $ 9.550 755 $ 9.560 150 $ 9.570 1,600 $ 9.590 100 $ 9.599 5,580 $ 9.600 400 $ 9.609 3,009 $ 9.610 4,875 $ 9.619 150 $ 9.620 500 $ 9.629 65 $ 9.639 450 $ 9.650 416 $ 9.660 425 $ 9.680 350 $ 9.690
DETAILS OF SALE OF 35,500 SHARES BY BOVF ON AUGUST 23, 2005
SHARES PRICE PER SHARE - ------ --------------- 267 $ 9.150 10,058 $ 9.500 350 $ 9.509 1,155 $ 9.510 1,100 $ 9.529 695 $ 9.530 3,050 $ 9.550 755 $ 9.560 150 $ 9.570 1,600 $ 9.590 100 $ 9.599 5,580 $ 9.600 400 $ 9.609 3,009 $ 9.610 4,875 $ 9.619 150 $ 9.620 500 $ 9.629 65 $ 9.639 450 $ 9.650 416 $ 9.660 425 $ 9.680 350 $ 9.690
ANNEX C DETAILS OF SALE BY BMVF OF 105,500 SHARES ON AUGUST 24, 2005
SHARES PRICE PER SHARE - ------ --------------- 1,850 $9.400 1,675 $9.410 800 $9.420 50 $9.430 900 $9.440 3,100 $9.450 1,250 $9.459 50 $9.460 25 $9.469 25 $9.479 25 $9.490 11,338 $9.500 1,950 $9.505 4,951 $9.509 4,567 $9.510 1,500 $9.519 4,440 $9.520 2,775 $9.529 2,875 $9.530 2,090 $9.539 3,538 $9.540 3,063 $9.549 3,489 $9.550 300 $9.560 343 $9.569 1,875 $9.570 952 $9.580 160 $9.589 7,329 $9.600 250 $9.609 3,204 $9.610 945 $9.619 1,262 $9.620 2,475 $9.629 144 $9.630 25 $9.640 425 $9.649 472 $9.650 1,000 $9.659 600 $9.670 250 $9.679 113 $9.680 100 $9.689 1,050 $9.690 700 $9.699 1,337 $9.700 254 $9.709 2,000 $9.710 500 $9.719 75 $9.720 2,350 $9.730 500 $9.739 718 $9.740 100 $9.749
1,568 $9.750 516 $9.759 250 $9.760 350 $9.770 1,100 $9.780 3,000 $9.789 2,925 $9.790 700 $9.799 400 $9.800 100 $9.809 500 $9.810 1,050 $9.820 100 $9.840 150 $9.859 900 $9.860 400 $9.870 2,550 $9.890 807 $9.920
DETAILS OF SALE BY BOVF OF 105,500 SHARES ON AUGUST 24, 2005
SHARES PRICE PER SHARE - ------ --------------- 1,850 $9.400 1,675 $9.410 800 $9.420 50 $9.430 900 $9.440 3,100 $9.450 1,250 $9.459 50 $9.460 25 $9.469 25 $9.479 25 $9.490 11,339 $9.500 1,950 $9.505 4,950 $9.509 4,567 $9.510 1,500 $9.519 4,440 $9.520 2,775 $9.529 2,875 $9.530 2,090 $9.539 3,539 $9.540 3,062 $9.549 3,489 $9.550 300 $9.560 344 $9.569 1,875 $9.570 952 $9.580 160 $9.589 7,328 $9.600 250 $9.609 3,204 $9.610 945 $9.619 1,263 $9.620 2,475 $9.629 143 $9.630 25 $9.640 425 $9.649 473 $9.650 1,000 $9.659 600 $9.670 250 $9.679 112 $9.680 100 $9.689 1,050 $9.690 700 $9.699 1,338 $9.700 253 $9.709 2,000 $9.710 500 $9.719 75 $9.720 2,350 $9.730 500 $9.739 719 $9.740 100 $9.749 1,567 $9.750
517 $9.759 250 $9.760 350 $9.770 1,100 $9.780 3,000 $9.789 2,925 $9.790 700 $9.799 400 $9.800 100 $9.809 500 $9.810 1,050 $9.820 100 $9.840 150 $9.859 900 $9.860 400 $9.870 2,550 $9.890 806 $9.920
EX-99.G 2 y12294exv99wg.txt EX-99.G: JOINT FILING AGREEMENT Exhibit G JOINT FILING STATEMENT The undersigned hereby agree as follows: (i) Each of them is individually eligible to use the Schedule 13D to which this Exhibit is attached, and such Schedule 13D is filed on behalf of each of them; and (ii) Each of them is responsible for the timely filing of such Schedule 13D and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate. Date: August 25, 2005 GREAT POINT PARTNERS LLC Signature: /s/ Dr. Jeffrey R. Jay, M.D. ------------------------------ By Dr. Jeffrey R. Jay, M.D., as senior managing member BIOMEDICAL VALUE FUND L.P. Signature: /s/ Dr. Jeffrey R. Jay, M.D. ------------------------------ By Great Point Partners, LLC, as investment manager, By Dr. Jeffrey R. Jay, M.D., as senior managing member BIOMEDICAL OFFSHORE VALUE FUND, LTD. Signature: /s/ D. Jeffrey R. Jay, M.D. ------------------------------ By Great Point Partners, LLC, as investment manager, By Dr. Jeffrey R. Jay, M.D., as senior managing member DR. JEFFREY R. JAY, M.D. Signature: /s/ Dr. Jeffrey R. Jay, M.D. ------------------------------ -----END PRIVACY-ENHANCED MESSAGE-----